To further evaluate the impact of MTA3 on the therapeutic effect of anti-PD-1 immunotherapy, we compared melanoma responders and nonresponders undergoing PD-1 blockade therapy from the immune checkpoint blockade datasets of the Gene Expression Omnibus (GEO) database and calculated the expression of MTA3 within each group. The gene discussed is PDCD1; the disease is melanoma.